VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

ALVAC-RV Rabies virus DNA vaccine pCMV-intA-rabies encoding glycoprotein G RCN-rabies-G
Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004728
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: A non-adjuvanted feline rabies vaccine developed using the canarypoxvirus vector (Jas et al., 2012).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004371
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse, cat, dog
  • G gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pCMV-intA expressed the rabies glycoprotein G (Osorio et al., 1999).
    • Detailed Gene Information: Click Here.
  • Vector: pCMV-intA (Osorio et al., 1999)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004693
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Glycoprotein G gene engineering:
    • Type: Recombinant vector construction
    • Description: A recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 1999).
    • Detailed Gene Information: Click Here.
  • Preparation: Recombinant RCN vaccine expressing the rabies-G glycoprotein (RCN/rabies-G) (Osorio et al., 2003).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response

Cat Response

  • Vaccination Protocol: Seronegative cats were vaccinated at 12 weeks of age and received a booster vaccination one year later (Jas et al., 2012).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The cats were challenged by inoculation of 1 mL of rabies virus in the neck muscles (0.5 mL on the left and right side of the spine). The inoculum was a homogenate of salivary glands of foxes and each cat received 107.7 mouse Lethal Dose 50, the equivalent of 106.8 CCID50.
  • Efficacy: This vaccination regimen induced a strong and sustained antibody response, and all vaccinated animals were protected against virulent rabies challenge carried out 3 years after vaccination (Jas et al., 2012).

Cat Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Neutralizing antibody responses following DNA vaccination lasted at least nine months with high levels of RVNA in all i.m.-vaccinated dogs, and eleven of twelve i.d.-vaccinated cats. This suggests that a DNA rabies vaccine can induce durable and protective immune responses against rabies infection in companion animals (Osorio et al., 1999).
  • Efficacy: The geometric mean RVNA titer in the combined intradermal cat groups at day 289 was 341, a titer that correlates with solid protection against rabies challenge. Thus, it is reasonable to conclude that the high neutralization activity observed in the studies described here will afford protection against challenge, even though a challenge study was not performed (Osorio et al., 1999).

Cat Response

  • Vaccination Protocol: The cats were vaccinated by the oral (PO), intranasal (IN), conjunctival (CO) or intranasal/conjunctival (IN/CO) route (dose: 10 plaque forming units or PFU) (Osorio et al., 2003).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: Because of humanitarian concerns, we did not perform rabies virus challenge on these cats. However, RVNA titers of 1:5 (0.69 log10) or greater in humans have been correlated with vaccine protection (Smith et al., 1996). Thus, it is reasonable to surmise that the high RVNA titers observed in the immunized cats could provide protection against challenge (Osorio et al., 2003).
  • Efficacy: The RVNA titers remained high when measured at six months post-vaccination, demonstrating that the recombinant vaccine administered via these routes is very efficient at inducing long-lasting immunity (Osorio et al., 2003).
References References References
Jas et al., 2012: Jas D, Coupier C, Toulemonde CE, Guigal PM, Poulet H. Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant rabies virus vaccine. Vaccine. 2012; 30(49); 6991-6996. [PubMed: 23059358].
Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].
Osorio et al., 1999: Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, Haynes JR, Stinchcomb DT. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 1999; 17(9-10); 1109-1116. [PubMed: 10195621].
Osorio et al., 2003: Osorio JE, Frank RS, Moss K, Taraska T, Powell T, Stinchcomb DT. Raccoon poxvirus as a mucosal vaccine vector for domestic cats. Journal of drug targeting. 2003; 11(8-10); 463-470. [PubMed: 15203914].